Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605891 · ClinicalTrials.gov registry record · Phase 2
Dose Finding Study of CHF 4226 for Treating Patients With COPD
A Phase 2 study, sponsored by Chiesi Farmaceutici S.p.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 278
- Enrollment target
NCT00605891: Completed Phase 2 study, sponsored by Chiesi Farmaceutici S.p.A..
NCT00605891 is a Phase 2 study that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 278 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (109% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00605891, a Phase 2 study, has completed, sponsored by Chiesi Farmaceutici S.p.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 278 participants
- Enrollment target
Study Summary
The purpose of this study is to identify the optimal once-daily dose of CHF 4226 to be further developed for the treatment of patients with COPD.
Interventions
- DRUG placebo
- DRUG carmoterol (CHF 4226)
- DRUG salmeterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
What the finished NCT00605891 record still lists
NCT00605891 is an interventional study that assigns participants to a tested intervention. The registered 278 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (109% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00605891 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00605891 about?
NCT00605891 is a clinical study titled "Dose Finding Study of CHF 4226 for Treating Patients With COPD". The purpose of this study is to identify the optimal once-daily dose of CHF 4226 to be further developed for the treatment of patients with COPD.
What is the current status of trial NCT00605891?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 278 participants. The study started on 2006-10. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00605891?
The interventions under investigation include: placebo (DRUG), carmoterol (CHF 4226) (DRUG), salmeterol (DRUG).
Who is sponsoring clinical trial NCT00605891?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00605891's enrollment target sits among peer trials
278 202nd of 2000 higher than 1,799 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
- NCT05489237 · 278 participants · Phase 1
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
- NCT05965245 · 278 participants · NA
Suubi-Mhealth: A Mobile Health Intervention to Address Depression Among Youth
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia